Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 08/11/22
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLETPRNewsWire • 06/28/22
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of DirectorsPRNewsWire • 06/17/22
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 05/10/22
Oncolytics Biotech, Inc. (ONCY) CEO Matthew Coffey on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 05/05/22
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer MeetingPRNewsWire • 05/04/22
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer MeetingPRNewsWire • 05/02/22
Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor ConferencePRNewsWire • 04/21/22
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational MedicinePRNewsWire • 04/14/22
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual ConferencePRNewsWire • 04/12/22
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual MeetingPRNewsWire • 04/08/22
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual MeetingPRNewsWire • 04/08/22
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer TrialPRNewsWire • 03/31/22
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing CohortPRNewsWire • 03/24/22
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer ActivityPRNewsWire • 03/17/22
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual MeetingPRNewsWire • 03/09/22
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual MeetingPRNewsWire • 03/09/22
Oncolytics Biotech, Inc. (ONCY) CEO Matthew Coffey on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational HighlightsPRNewsWire • 03/03/22
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer TrialPRNewsWire • 02/02/22